National Institutes of Health, a Component of the US Dept. of Health & Human Services

Heidi R Bokesch

James Brislin McMahon

Curtis J Henrich

Michael C Dean

Susan Elaine Bates

Robert W Robey

Suneet Shukla

Suresh V Ambudkar

Kirk R Gustafson

Richard W Fuller

Kentaro Takada

Laura K Cartner

Michael R Boyd

Barry R O'Keefe

Tawnya C McKee

Nancy H Colburn

Matthew R Young

Moon-II Kang

Tawnya C Mckee

Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2 or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering peliomycin and other compounds described herein.

Method of inhibiting ABCG2 and related treatments

Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): wherein R, R, R, X, X, X, a, and b are as described herein. Uses of these compounds in the preparation of a medicament are also disclosed. Also disclosed are compounds of formula (II), pharmaceutical compositions comprising such compounds and uses thereof.

Method of inhibiting ABCG2 and other treatment methods

An embodiment of the invention provides a pharmaceutical composition comprising a compound of formula (I) a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Another embodiment of the invention provides a method of treating or preventing a condition associated with increased expression and/or activity of an NF&#x3ba;B pathway using same compounds. A further embodiment of the invention provides a method of diagnosing a condition in an individual using same compounds. 

Nuclear factor kappa B pathway inhibitor composition and use of same

Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): Formula (I), wherein R, R, R, X, X, X, a, and b are as described herein. Uses of these compounds in the preparation of a medicament are also disclosed. Also disclosed are compounds of formula (II), pharmaceutical compositions comprising such compounds and uses thereof. 

Botryllamides and method of inhibiting PGP in a mammal afflicted with cancer

An isolated or purified antiviral protein of SEQ ID NO: 1, nucleic acids encoding the antiviral protein, cells comprising the nucleic acids, and methods of inhibiting viral infection comprising contacting the virus with the antiviral protein.

Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins

Growing community of inventors

Frederick, MD, United States of America

Heidi R Bokesch